Drug Trial Radar · NCT04349631
A Clinical Trial to Determine the Safety and Efficacy of HB-adMSCs to Provide Protection Against COVID-19
Last checked: Nov 20, 2026Latest source record: Sep 26, 2025 (this record)Source: ClinicalTrials.govMethods & limitations
Status
Completed
Enrollment
51
Actual
Start
Apr 20, 2020
Primary completion
Nov 25, 2020
Study completion Nov 25, 2020
Sponsor
- Lead sponsor
- Hope Biosciences Research FoundationIndustry
- Sponsor type
- Industry
- First posted
- Apr 16, 2020
Design
- Study type
- Interventional
- Phase
- Phase 2
- Allocation
- Not applicable (single group)
- Model
- Single group
- Masking
- None
- Primary purpose
- Prevention
- FDA-regulated drug
- Yes
- Who can join
- All sexes
- Healthy volunteers
- Yes
Summary
As written by the sponsor on the registry.
Hope Biosciences is conducting a research study of an investigational product called autologous adipose-derived mesenchymal stem cells (abbreviated as HB-adMSCs) to provide immune support against COVID-19. The study purpose is to evaluate the safety and efficacy of five IV infusions of HB-adMSCs in subjects with no signs of COVID-19.
Conditions
- COVID-19
Interventions
HB-adMSCsBiological
Five IV infusions of autologous adipose-derived mesenchymal stem cells. Baseline laboratory values will be collected prior to first infusion and compared at following visits. Safety labs will be assessed at weeks 6, 14, 26. Inflammatory markers will be assessed at weeks 6, 14, 26. SF-36 and PHQ-9 questionnaires will be assessed at weeks 2, 6, 10, 14, 18, 22, 26.
Primary outcomes
What the sponsor says the trial is designed to measure.
- Incidence of Hospitalization for COVID-19Time frame: Week 0 through Week 26 (End of Study)
- Incidence of Symptoms for COVID-19Time frame: Week 0 through Week 26 (End of Study)
Locations
1 site in 1 country. Site status is shown where the registry gives one.
Hope Biosciences Stem Cell Research Foundation
Sugar Land, Texas
Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.